


**2. AMENDMENTS IN THE CLAIMS:**

*This listing of claims will replace all prior versions and listings of claims in the application:*

*Listing of the Claims:*

1. (Original) A method of treatment of osteoarthritis, comprising the step of administering an effective amount of an inhibitor of a G protein-coupled receptor to a subject in need of such treatment, in which the inhibitor is a compound which
  - (a) is an antagonist of a G protein-coupled receptor,
  - (b) has substantially no agonist activity, and
  - (c) is a cyclic peptide or peptidomimetic compound of formula I



where A is H, alkyl, aryl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, NH-aryl, NH-acyl, NH-benzoyl, NHSO<sub>3</sub>, NHSO<sub>2</sub>-alkyl, NHSO<sub>2</sub>-aryl, OH, O-alkyl, or O-aryl;

B is an alkyl, aryl, phenyl, benzyl, naphthyl or indole group, or the side chain of a D- or L-amino acid, but is not the side chain of glycine, D-phenylalanine, L-homophenylalanine, L-tryptophan, L-homotryptophan, L-tyrosine, or L-homotyrosine;

C is the side chain of a D-, L- or homo-amino acid, but is not the side chain of isoleucine, phenylalanine, or cyclohexylalanine;

D is the side chain of a neutral D-amino acid, but is not the side chain of glycine or D-alanine, a bulky planar side chain, or a bulky charged side chain;

E is a bulky substituent, but is not the side chain of D-tryptophan, L-N-methyltryptophan, L-homophenylalanine, L-2-naphthyl L-tetrahydroisoquinoline, L-cyclohexylalanine, D-leucine, L-fluorenylalanine, or L-histidine;

F is the side chain of L-arginine, L-homoarginine, L-citrulline, or L-canavanine, or a bioisostere thereof; and

X is  $-(CH_2)_nNH-$  or  $(CH_2)_nS-$ , where n is an integer of from 1 to 4;  $-(CH_2)_2O-$ ;  $-(CH_2)_3O-$ ;  $-(CH_2)_3-$ ;  $-(CH_2)_4-$ ;  $-CH_2COCHRNH-$ ; or  $-CH_2CHCOCHRNH-$ , where R is the side chain of any common or uncommon amino acid.

2. (Original) A method according to claim 1, in which n is 2 or 3.
3. (Original) A method according to claim 1, in which A is an acetamide group, an aminomethyl group, or a substituted or unsubstituted sulphonamide group.
4. (Original) A method according to claim 2, in which A is a substituted sulphonamide, and the substituent is an alkyl chain of 1 to 6 carbon atoms, or a phenyl or tolyl group.
5. (Original) A method according to claim 3, in which the substituent is an alkyl chain of 1 to 4 carbon atoms.

6. (Original) A method according to claim 1, in which B is the side chain of L-phenylalanine or L-phenylglycine.
7. (Original) A method according to claim 1, in which C is the side chain of glycine, alanine, leucine, valine, proline, hydroxyproline, or thioproline.
8. (Original) A method according to claim 1, in which D is the side chain of D-Leucine, D-homoleucine, D-cyclohexylalanine, D-homocyclohexylalanine, D-valine, D-norleucine, D-homo-norleucine, D-phenylalanine, D-tetrahydroisoquinoline, D-glutamine, D-glutamate, or D-tyrosine.
9. (Original) A method according to claim 1, in which E is the side chain of an amino acid selected from the group consisting of L-phenylalanine, L-tryptophan and L-homotryptophan, or is L-1-naphthyl or L-3-benzothienyl alanine.
10. (Original) A method according to claim 1, in which the inhibitor is a compound which has antagonist activity against C5aR, and has no C5a agonist activity.
11. (Original) A method according to claim 1, in which the inhibitor has potent antagonist activity at sub-micromolar concentrations.
12. (Currently Amended) A method according to claim 1, in which the compound has a receptor affinity  $IC_{50} < 25 \mu M$ , and an antagonist potency  ~~$IC_{50} < 1 \mu M$~~   $IC_{50} < 1 \mu M$ .
13. (Original) A method according to claim 1, in which the compound is selected from the group consisting of compounds 1 to 6, 10 to 15, 17, 19, 20, 22, 25, 26, 28, 30, 31, 33 to 37, 39 to 45, 47 to 50, 52 to 58 and 60 to 70 described in PCT/AU02/01427.
14. (Original) A method according to claim 13, in which the compound is compound 1 (AcF-[OP-DCha-WR]), compound 33 (AcF-[OP-DPhe-WR]), compound 60 (AcF-[OP-DCha-FR]) or compound 45 (AcF-[OP-DCha-WCit]) described in PCT/AU02/01427.

15. (Original) A method according to claim 1, in which the inhibitor is used in conjunction with one or more other agents for the treatment of osteoarthritis.